olopatadine and mometasone
Ryaltris is a nasal spray from Glenmark that combines olopatadine, an antihistamine, with mometasone, a corticosteroid. It treats the symptoms of seasonal allergic rhinitis in adults and children aged 6 years and older, easing sneezing, itching, runny nose, and congestion.
This page is based on the FDA labeling for Ryaltris and the Health Canada product record; the EMA and openFDA records in the evidence bundle refer to other olopatadine products and were not used for indications.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Allergic rhinitis is a two-part fire in the nose: histamine sparks the instant itch, sneeze, and drip, and inflammation keeps the lining swollen afterward. Ryaltris fights both fronts at once. Olopatadine blocks the histamine sparks, while mometasone quiets the smouldering inflammation, so the nose settles down through the allergy season.
In simple terms
Ryaltris combines two medicines in one nasal spray. Olopatadine is an antihistamine that blocks histamine, the substance released during an allergic reaction that causes sneezing, itching, and a runny nose. Mometasone is a corticosteroid that reduces inflammation and swelling in the nasal passages. Used together, they relieve the nasal symptoms of seasonal allergic rhinitis more completely than either approach alone. The spray acts locally in the nose.
In depth
Ryaltris is a fixed-dose combination nasal spray of olopatadine hydrochloride, a selective histamine H1-receptor antagonist, and mometasone furoate, a corticosteroid. Olopatadine competitively blocks histamine at H1 receptors on nasal sensory and vascular tissues, reducing sneezing, pruritus, and rhinorrhoea, while mometasone furoate binds the glucocorticoid receptor and suppresses the transcription of inflammatory mediators, reducing mucosal oedema and late-phase allergic inflammation. The combination is approved for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients aged six years and older.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
Ryaltris fights both fronts at once
- Allergic rhinitis is a two-part fire in the nose: histamine sparks the instant itch, sneeze, and drip, and inflammation keeps the lining swollen afterward.
- Ryaltris combines two medicines in one nasal spray.
- Olopatadine competitively blocks histamine at H1 receptors on nasal sensory and vascular tissues, reducing sneezing, pruritus, and rhinorrhoea, while mometasone furoate binds the glucocorticoid receptor and suppresses the transcription of inflammatory mediators, reducing mucosal oedema and late-phase allergic inflammation.
- The spray acts locally in the nose.
Target: Histamine H1 receptors and the glucocorticoid receptor
Histamine drives the immediate itch, sneeze, and drip of allergic rhinitis through H1 receptors, while the glucocorticoid receptor controls the broader inflammatory response in the nasal lining; the combination addresses both.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- For the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older
Official sources
The statements on this page trace back to these records.
- DailyMed: RYALTRIS (olopatadine and mometasone) official US label
U.S. National Library of Medicine, DailyMed
- Health Canada Drug Product Database: RYALTRIS
Health Canada
- U.S. Food and Drug Administration: olopatadine prescribing information
U.S. Food and Drug Administration
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.